BiotechTube

Mirabegron + Placebo + Tamsulosin Hydrochloride

ApprovedCompleted
0 views this week 0 watching⚡ Active
Interest: 43/100
43
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
✓
Phase 3
5
Approved
Indication / Disease

Benign Prostatic Hyperplasia

Conditions

Benign Prostatic Hyperplasia, Overactive Bladder

Trial Timeline

Jun 13, 2016 → Sep 11, 2018

NCT ID
NCT02757768

About Mirabegron + Placebo + Tamsulosin Hydrochloride

Mirabegron + Placebo + Tamsulosin Hydrochloride is a approved stage product being developed by Astellas Pharma for Benign Prostatic Hyperplasia. The current trial status is completed. This product is registered under clinical trial identifier NCT02757768. Target conditions include Benign Prostatic Hyperplasia, Overactive Bladder.

What happened to similar drugs?

7 of 20 similar drugs in Benign Prostatic Hyperplasia were approved

Approved (7) Terminated (3) Active (10)
🔄Tadalafil + PlaceboEli LillyPhase 3
🔄5 mg Tadalafil + Placebo + 0.2 mg TamsulosinEli LillyPhase 3
🔄Placebo + tadalafilEli LillyPhase 3
✅Tadalafil + Placebo + Alpha1 BlockerEli LillyApproved
🔄Placebo tamsulosin hydrochloride OCAS 0.4 mg + Placebo FDC tamsulosin hydrochloride/solifenacin succinate 0.4 mg/6 mg + Placebo FDC tamsulosin hydrochloride/solifenacin succinate 0.4 mg/9 mg + tamsulosin hydrochloride OCAS 0.4 mg + tamsulosin hydrochloride/solifenacin succinate fixed dose combination (0.4 mg/6 mg) + tamsulosin hydrochloride/solifenacin succinate fixed dose combination (0.4 mg/9 mg)Astellas PharmaPhase 3
✅Tamsulosin hydrochloride + Solifenacin succinateAstellas PharmaApproved
✅Tamsulosin OCASAstellas PharmaApproved

Hype Score Breakdown

Clinical
20
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT02757768ApprovedCompleted

Competing Products

20 competing products in Benign Prostatic Hyperplasia

See all competitors
ProductCompanyStageHype Score
Tadalafil + PlaceboEli LillyPhase 3
40
5 mg Tadalafil + Placebo + 0.2 mg TamsulosinEli LillyPhase 3
40
Placebo + tadalafilEli LillyPhase 3
40
Tadalafil + Placebo + Alpha1 BlockerEli LillyApproved
43
Placebo tamsulosin hydrochloride OCAS 0.4 mg + Placebo FDC tamsulosin hydrochloride/solifenacin succinate 0.4 mg/6 mg + Placebo FDC tamsulosin hydrochloride/solifenacin succinate 0.4 mg/9 mg + tamsulosin hydrochloride OCAS 0.4 mg + tamsulosin hydrochloride/solifenacin succinate fixed dose combination (0.4 mg/6 mg) + tamsulosin hydrochloride/solifenacin succinate fixed dose combination (0.4 mg/9 mg)Astellas PharmaPhase 3
40
ASP4901 + Tamsulosin + PlaceboAstellas PharmaPhase 2
35
Tamsulosin hydrochloride + Solifenacin succinateAstellas PharmaApproved
43
Tamsulosin OCASAstellas PharmaApproved
43
Tamsulosin OCAS + PlaceboAstellas PharmaApproved
43
Tamsulosin + Finasteride + PlaceboAstellas PharmaApproved
39
Tadalafil + PlaceboEli LillyPhase 2
35
TadalafilEli LillyPhase 1
29
Tadalafil + Placebo + TamsulosinEli LillyPhase 3
40
Tadalafil 2.5 mg + Tadalafil 5 mg + PlaceboEli LillyPhase 2
35
Tadalafil 5 mg + Placebo tablet + Tamsulosin + Placebo capsuleEli LillyPhase 3
40
Tadalafil + PlaceboEli LillyPhase 3
40
Tadalafil + Placebo + TamsulosinEli LillyPhase 2
35
Tadalafil + PlaceboEli LillyPhase 3
40
tadalafil + tadalafil + tadalafil + tadalafil + placeboEli LillyPhase 2/3
38
Tadalafil + Placebo + FinasterideEli LillyPhase 3
40